Tempus Ai Cl A (TEM) Stock Price, Quote & News

Company Profile

Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services...

Industry: Health Information Services

Sector: Healthcare

Phone: 800 976 5448

Fax: 800 893 0276

Website: www.tempus.com

Address:

600 West Chicago Avenue, Suite 510, Chicago, United States

Merlintrader Feb. 17 at 8:00 AM

$TEM https://www.merlintrader.com/ai-in-biotech/

0 · Reply

JayBirdEvans Feb. 15 at 9:30 PM

$TEM https://www.stocktitan.net/sec-filings/PSNL/form-4-personalis-inc-insider-trading-activity-977213942afd.html

0 · Reply

QuantInsider Feb. 14 at 1:20 AM

$TEM saw a nice +2.3% bounce today but don't get too excited We're still down about 2.8% over five days Big money's not convinced Over $3.7M in deep ITM Feb $67 to $70 puts traded, way above prior open interest Implied vol over 200 percent, that’s some serious downside protection being added More than 90% of the 5-day options premium has gone into puts Today’s bullish flow was just two far OTM Mar 20 $80 and $90 calls, totaling around $43K Feels like cheap speculation, not real conviction Caution here This bounce looks more like a rally into a defensive setup than anything else

0 · Reply

dcrown Feb. 14 at 12:09 AM

$TEM is temp a real ai company or is best described as a hybrid health-technology company? company was renamed from "Tempus Labs" to "Tempus AI" in 2023, suggesting the rebrand was designed to capitalize on AI market hype

1 · Reply

BeeDecay Feb. 13 at 10:43 PM

$PSNL seems like $TEM acquired some extra shares…

1 · Reply

ZacksResearch Feb. 13 at 3:29 PM

$TEM: Stellar growth but is it too pricey? 🚀💰 Tempus reported an impressive 83% revenue growth for the full year, including 30% organic growth excluding Ambry, fueled by a 111% jump in diagnostics. Yet, with a P/B ratio of 17.79X, it looks overvalued compared to peers. Understand the risks before investing in TEM 👉 https://www.zacks.com/stock/news/2868889/should-you-buy-hold-or-sell-tempus-ai-stock-pre-q4-earnings-release?cid=sm-stocktwits-2-2868889-body-33505&ADID=SYND_STOCKTWITS_TWEET_2_2868889_BODY_33505

0 · Reply

NakropBannok Feb. 13 at 2:45 PM

$TEM 55 🆙 for president day 💪

0 · Reply

ZacksResearch Feb. 13 at 2:29 PM

$TEM into Q4 — explosive growth or valuation trap? 🤔 Preliminary, unaudited results show 83% revenue growth and record data sales in 2025, but ongoing GAAP losses and a stretched valuation are keeping the risk/reward debate alive heading into earnings. Big momentum… but can the fundamentals justify the price? Full bull/bear breakdown before Q4 👉 https://www.zacks.com/stock/news/2868889/should-you-buy-hold-or-sell-tempus-ai-stock-pre-q4-earnings-release?cid=sm-stocktwits-2-2868889-teaser-33501&ADID=SYND_STOCKTWITS_TWEET_2_2868889_TEASER_33501

0 · Reply

theoptionsplug Feb. 13 at 1:51 AM

Cathie Wood's buys today include: • $13M $SHOP • $12M $HOOD • $11M $TEM • $9M $RBLX • $4M $BMNR

1 · Reply

rooneyray Feb. 12 at 6:42 PM

$TEM Started a position here even though there may be dilution risks coming soon. Love the financials, love the growth and love the margins on this company. The moat they're building is also incredible. This will be the Palantir of healthcare. $TEM and $TWST is the perfect pure play to bio and life sciences and couples a healthy alpha with a great hint of beta. Anyone looking for hidden alphas in the stock market should flock to these two. My only worry with TEM is short term dilution risks with more acquisitions that may be underway, but in the long term, this will all have been noise.

3 · Reply

Tempus Announces Collaboration with Median Technologies to Integrate AI-Powered Lung Cancer Screening into the Pixel Platform

Feb 12, 2026, 4:05 PM EST - 4 days ago

Median Technologies Announces Collaboration With Tempus to Expand Access to eyonis® LCS Software as a Medical Device in the United States

Feb 10, 2026, 8:30 AM EST - 6 days ago

Tempus to Report Fourth Quarter and Full Year 2025 Financial Results on February 24

Feb 4, 2026, 7:00 AM EST - 12 days ago

Ambry's Contributions to MAVEs Support Thousands of Patient Reclassifications and Expand to New Genes

Feb 2, 2026, 7:00 AM EST - 14 days ago

Ambry Genetics Announces One Millionth Test Leveraging RNA to Improve Diagnostic Accuracy and Yield

Jan 27, 2026, 8:30 AM EST - 20 days ago

Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers

Jan 26, 2026, 11:14 AM EST - 21 days ago

Tempus Logix Launches AI-Powered Calculator to End Hidden Fees and Price Fluctuation in Auto Transport

Jan 23, 2026, 9:44 AM EST - 24 days ago

Tempus AI: Staying Bullish On Leading Healthcare AI Play

Jan 22, 2026, 8:00 AM EST - 25 days ago

Tempus AI Highlights Strong Growth At The J.P. Morgan Healthcare Conference

Jan 21, 2026, 8:30 AM EST - 26 days ago

Tempus Announces the Launch of Paige Predict

Jan 12, 2026, 7:05 PM EST - 5 weeks ago

Tempus AI, Inc. (TEM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 8:30 AM EST - 5 weeks ago

Tempus and NYU Langone Health Announce Strategic Collaboration to Advance Precision Oncology

Jan 12, 2026, 8:00 AM EST - 5 weeks ago

Here's why the Tempus AI stock may surge 47% soon

Jan 12, 2026, 7:00 AM EST - 5 weeks ago

Northwestern Medicine Selects Tempus to Expand Genomic Testing

Jan 12, 2026, 5:33 AM EST - 5 weeks ago

Stock Market Today: Dow Jones, S&P 500 Futures Tumble As DOJ Serves Federal Reserve—Vistra, Tempus AI, Alibaba In Focus

BABA IVV SPXL SPY SSO UPRO VOO

Jan 11, 2026, 5:30 PM EST - 5 weeks ago

Tempus Achieves Record Total Contract Value Exceeding $1.1 Billion

Jan 11, 2026, 5:00 PM EST - 5 weeks ago

Tempus Announces Preliminary Fourth Quarter and Full Year 2025 Results

Jan 8, 2026, 8:30 AM EST - 5 weeks ago

Tempus Announces Eight Abstracts Accepted for Presentation at the 2026 ASCO® Gastrointestinal Cancers Symposium

Jan 8, 2026, 8:15 AM EST - 5 weeks ago

Rune Labs Taps Tempus Exec as New CEO to Expand AI-Enabled Neurology Care

Jan 6, 2026, 8:30 AM EST - 5 weeks ago

Tempus to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 7:05 AM EST - 2 months ago

Tempus AI: A Healthcare Hyper-Growth Opportunity For The Risk Tolerant

Dec 18, 2025, 7:00 AM EST - 2 months ago

Top 3 Health Care Stocks You'll Regret Missing This Quarter

INSM LEGN

Dec 16, 2025, 10:13 AM EST - 2 months ago

Tempus AI: Plenty Of Growth Catalysts Ahead, Grab It While It's Down

Dec 9, 2025, 8:30 AM EST - 2 months ago

Tempus Announces Ten Abstracts Accepted for Presentation at the 2025 San Antonio Breast Cancer Symposium

Dec 3, 2025, 12:53 PM EST - 2 months ago

Tempus AI, Inc. (TEM) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Nov 18, 2025, 8:30 AM EST - 3 months ago

Tempus to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 15, 2025, 10:00 AM EST - 3 months ago

Tempus AI: Opportunity To Build Position

Nov 14, 2025, 8:30 AM EST - 3 months ago

Tempus and IFLI Announce Study to Advance Follicular Lymphoma Research

Nov 13, 2025, 12:11 PM EST - 3 months ago

Tempus AI, Inc. (TEM) Presents at Stifel 2025 Healthcare Conference Transcript

Nov 13, 2025, 9:59 AM EST - 3 months ago

Tempus AI: Great Buying Opportunity On Recent Weakness

Nov 12, 2025, 5:34 PM EST - 3 months ago

Tempus AI: A Good Bet For The Future Of Health Care

Nov 10, 2025, 9:55 PM EST - 3 months ago

Tempus AI: First Positive EBITDA, Huge TAM - Yet The Stock Isn't A Buy

Nov 5, 2025, 1:00 PM EST - 3 months ago

Tempus AI Growth Outlook Boosted By Higher ASPs, Pharma Contracts, Analyst Says

Nov 5, 2025, 8:30 AM EST - 3 months ago

Tempus Announces Six Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer Annual Meeting 2025

Nov 4, 2025, 7:06 PM EST - 3 months ago

Tempus AI, Inc. (TEM) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 4:01 PM EST - 3 months ago

Tempus Reports Third Quarter 2025 Results

Oct 28, 2025, 8:30 AM EDT - 3 months ago

Tempus to Participate in the Stifel 2025 Healthcare Conference

Oct 21, 2025, 8:30 AM EDT - 4 months ago

Tempus to Report Third Quarter 2025 Financial Results on November 4

Oct 20, 2025, 9:00 AM EDT - 4 months ago

Ambry Genetics Announces 10-Year Study in Genetics in Medicine Highlighting the Impact of Proactive Exome Reanalysis for Healthcare Equity

Oct 16, 2025, 8:30 AM EDT - 4 months ago

Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research

WHWK

Oct 15, 2025, 8:30 AM EDT - 4 months ago

Tempus Announces Six Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025

Oct 9, 2025, 8:30 AM EDT - 4 months ago

Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer Therapy

Oct 9, 2025, 8:24 AM EDT - 4 months ago

Tempus AI's $100 Breakout — Billionaire Cliff Asness Reaps 60% Windfall

Oct 1, 2025, 12:24 PM EDT - 4 months ago

Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution with Upgraded Tyrer-Cuzick Scoring Approach Incorporating Breast Density

Sep 22, 2025, 4:30 PM EDT - 5 months ago

Overlooked Stock: TEM Taps All-Time High on FDA Clearance

Sep 22, 2025, 8:30 AM EDT - 5 months ago

Tempus Receives U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS In Vitro Diagnostic Device

Sep 15, 2025, 8:00 AM EDT - 5 months ago

Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease

Sep 12, 2025, 1:09 PM EDT - 5 months ago

Tempus AI stock is cheap as Murrey Math Lines points to more gains

Sep 12, 2025, 10:05 AM EDT - 5 months ago

Tempus AI: Is TEM Stock A 10x Growth Story?

Sep 11, 2025, 1:58 PM EDT - 5 months ago

Tempus AI Gains FDA Clearance For Updated Pixel To Boost Accuracy And Efficiency In Cardiac Imaging

Merlintrader Feb. 17 at 8:00 AM

$TEM https://www.merlintrader.com/ai-in-biotech/

0 · Reply

JayBirdEvans Feb. 15 at 9:30 PM

$TEM https://www.stocktitan.net/sec-filings/PSNL/form-4-personalis-inc-insider-trading-activity-977213942afd.html

0 · Reply

QuantInsider Feb. 14 at 1:20 AM

0 · Reply

dcrown Feb. 14 at 12:09 AM

1 · Reply

BeeDecay Feb. 13 at 10:43 PM

$PSNL seems like $TEM acquired some extra shares…

1 · Reply

ZacksResearch Feb. 13 at 3:29 PM

0 · Reply

NakropBannok Feb. 13 at 2:45 PM

$TEM 55 🆙 for president day 💪

0 · Reply

ZacksResearch Feb. 13 at 2:29 PM

0 · Reply

theoptionsplug Feb. 13 at 1:51 AM

Cathie Wood's buys today include: • $13M $SHOP • $12M $HOOD • $11M $TEM • $9M $RBLX • $4M $BMNR

1 · Reply

rooneyray Feb. 12 at 6:42 PM

3 · Reply

Tracepeden3 Feb. 12 at 4:56 PM

$TEM to any of my trader people if $50 holds can we expect upward movement? And if it doesn’t where can we expect price to go from there?

2 · Reply

bigwigspix Feb. 12 at 4:37 PM

$TEM In 50.02

0 · Reply

dukeofhb Feb. 12 at 4:36 PM

$TEM carnage since October. Bitcoin high

0 · Reply

50bps Feb. 12 at 4:10 PM

$TEM classic cathie effect

2 · Reply

BullYa Feb. 12 at 4:04 PM

$TEM 📉 $45 tmrw or Monday

1 · Reply

davidduong Feb. 12 at 2:58 PM

$TEM wow $35M awarded and still dropping... wtf happened... smh 🤯

2 · Reply

jonini Feb. 12 at 2:58 PM

$TEM 아오 미친병신새끼

1 · Reply

davidduong Feb. 12 at 1:48 PM

$NVDA $QQQ $TEM Big Green today

0 · Reply

davidduong Feb. 12 at 1:45 PM

$TEM was awarded $35,239,692.50 on February 11, 2026, by the Strategic Acquisition Center (SAC) to support precision medicine initiative

0 · Reply

davidduong Feb. 12 at 1:42 PM

$TEM must be bounce at $56 -$57 now ...

1 · Reply

GoldmanSlaps Feb. 11 at 11:24 PM

$TEM no bounce on this news? Wtf

1 · Reply

MKRReformed Feb. 11 at 11:07 PM

$TEM under $50 is a buy imo Nibbling reload, just 10% of planned allotment

2 · Reply

Market Cap	9.24B
Revenue (ttm)	693.40M
Net Income (ttm)	-705.81M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-101.79%
Debt to Equity Ratio	0.59

Volume	3,137,400
Avg Vol	4,822,664
Day's Range	N/A - N/A
Shares Out	177.91M
Stochastic %K	26%
Beta	5.22
Analysts	Sell
Price Target	$87.92